364 related articles for article (PubMed ID: 31865062)
1. Naquotinib exerts antitumor activity in activated B-cell-like diffuse large B-cell lymphoma.
Tanaka H; Kaneko N; Sakagami H; Matsuya T; Hiramoto M; Yamanaka Y; Mori M; Koshio H; Hirano M; Takeuchi M
Leuk Res; 2020 Jan; 88():106286. PubMed ID: 31865062
[TBL] [Abstract][Full Text] [Related]
2. Activation of unfolded protein response overcomes Ibrutinib resistance in diffuse large B-cell lymphoma.
Zhang XT; Hu XB; Wang HL; Kan WJ; Xu L; Wang ZJ; Xiang YQ; Wu WB; Feng B; Li JN; Gao AH; Dong TC; Xia CM; Zhou YB; Li J
Acta Pharmacol Sin; 2021 May; 42(5):814-823. PubMed ID: 32855532
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumor efficacy study of the Bruton's tyrosine kinase (BTK) inhibitor, ONO/GS-4059, in combination with the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab (GA101) demonstrates superior in vivo efficacy compared to ONO/GS-4059 in combination with rituximab.
Yasuhiro T; Sawada W; Klein C; Kozaki R; Hotta S; Yoshizawa T
Leuk Lymphoma; 2017 Mar; 58(3):699-707. PubMed ID: 27684575
[TBL] [Abstract][Full Text] [Related]
4. Single and combined BTK and PI3Kδ inhibition with acalabrutinib and ACP-319 in pre-clinical models of aggressive lymphomas.
Spriano F; Tarantelli C; Gaudio E; Gerlach MM; Priebe V; Cascione L; Bernasconi E; Targa A; Mascia M; Dirnhofer S; Stathis A; Zucca E; Bertoni F
Br J Haematol; 2019 Dec; 187(5):595-601. PubMed ID: 31355927
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma.
Sasi BK; Martines C; Xerxa E; Porro F; Kalkan H; Fazio R; Turkalj S; Bojnik E; Pyrzynska B; Stachura J; Zerrouqi A; Bobrowicz M; Winiarska M; Priebe V; Bertoni F; Mansouri L; Rosenquist R; Efremov DG
Leukemia; 2019 Oct; 33(10):2416-2428. PubMed ID: 30872780
[TBL] [Abstract][Full Text] [Related]
6. The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma.
Kuo HP; Ezell SA; Hsieh S; Schweighofer KJ; Cheung LW; Wu S; Apatira M; Sirisawad M; Eckert K; Liang Y; Hsu J; Chen CT; Beaupre D; Chang BY
Am J Cancer Res; 2016; 6(11):2489-2501. PubMed ID: 27904766
[TBL] [Abstract][Full Text] [Related]
7. A Novel BCL-2 Inhibitor APG-2575 Exerts Synthetic Lethality With BTK or MDM2-p53 Inhibitor in Diffuse Large B-Cell Lymphoma.
Luo Q; Pan W; Zhou S; Wang G; Yi H; Zhang L; Yan X; Yuan L; Liu Z; Wang J; Chen H; Qiu M; Yang D; Sun J
Oncol Res; 2020 Sep; 28(4):331-344. PubMed ID: 32093809
[TBL] [Abstract][Full Text] [Related]
8. Role of Bruton's tyrosine kinase in B cells and malignancies.
Pal Singh S; Dammeijer F; Hendriks RW
Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
[TBL] [Abstract][Full Text] [Related]
9. Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma.
Kuo HP; Ezell SA; Schweighofer KJ; Cheung LWK; Hsieh S; Apatira M; Sirisawad M; Eckert K; Hsu SJ; Chen CT; Beaupre DM; Versele M; Chang BY
Mol Cancer Ther; 2017 Jul; 16(7):1246-1256. PubMed ID: 28428442
[TBL] [Abstract][Full Text] [Related]
10. PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.
Yahiaoui A; Meadows SA; Sorensen RA; Cui ZH; Keegan KS; Brockett R; Chen G; Quéva C; Li L; Tannheimer SL
PLoS One; 2017; 12(2):e0171221. PubMed ID: 28178345
[TBL] [Abstract][Full Text] [Related]
11. BTK kinase activity is dispensable for the survival of diffuse large B-cell lymphoma.
Yuan H; Zhu Y; Cheng Y; Hou J; Jin F; Li M; Jia W; Cheng Z; Xing H; Liu M; Han T
J Biol Chem; 2022 Nov; 298(11):102555. PubMed ID: 36183831
[TBL] [Abstract][Full Text] [Related]
12. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.
Davis RE; Ngo VN; Lenz G; Tolar P; Young RM; Romesser PB; Kohlhammer H; Lamy L; Zhao H; Yang Y; Xu W; Shaffer AL; Wright G; Xiao W; Powell J; Jiang JK; Thomas CJ; Rosenwald A; Ott G; Muller-Hermelink HK; Gascoyne RD; Connors JM; Johnson NA; Rimsza LM; Campo E; Jaffe ES; Wilson WH; Delabie J; Smeland EB; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Pierce SK; Staudt LM
Nature; 2010 Jan; 463(7277):88-92. PubMed ID: 20054396
[TBL] [Abstract][Full Text] [Related]
13. BTK and PI3K Inhibitors Reveal Synergistic Inhibitory Anti-Tumoral Effects in Canine Diffuse Large B-Cell Lymphoma Cells.
Kong W; Sender S; Taher L; Villa-Perez S; Ma Y; Sekora A; Ruetgen BC; Brenig B; Beck J; Schuetz E; Junghanss C; Nolte I; Murua Escobar H
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884478
[TBL] [Abstract][Full Text] [Related]
14. Investigation of the anti-tumor mechanism of tirabrutinib, a highly selective Bruton's tyrosine kinase inhibitor, by phosphoproteomics and transcriptomics.
Kozaki R; Yasuhiro T; Kato H; Murai J; Hotta S; Ariza Y; Sakai S; Fujikawa R; Yoshida T
PLoS One; 2023; 18(3):e0282166. PubMed ID: 36897912
[TBL] [Abstract][Full Text] [Related]
15. Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition.
Liclican A; Serafini L; Xing W; Czerwieniec G; Steiner B; Wang T; Brendza KM; Lutz JD; Keegan KS; Ray AS; Schultz BE; Sakowicz R; Feng JY
Biochim Biophys Acta Gen Subj; 2020 Apr; 1864(4):129531. PubMed ID: 31953125
[TBL] [Abstract][Full Text] [Related]
16. A multiprotein supercomplex controlling oncogenic signalling in lymphoma.
Phelan JD; Young RM; Webster DE; Roulland S; Wright GW; Kasbekar M; Shaffer AL; Ceribelli M; Wang JQ; Schmitz R; Nakagawa M; Bachy E; Huang DW; Ji Y; Chen L; Yang Y; Zhao H; Yu X; Xu W; Palisoc MM; Valadez RR; Davies-Hill T; Wilson WH; Chan WC; Jaffe ES; Gascoyne RD; Campo E; Rosenwald A; Ott G; Delabie J; Rimsza LM; Rodriguez FJ; Estephan F; Holdhoff M; Kruhlak MJ; Hewitt SM; Thomas CJ; Pittaluga S; Oellerich T; Staudt LM
Nature; 2018 Aug; 560(7718):387-391. PubMed ID: 29925955
[TBL] [Abstract][Full Text] [Related]
17. Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma.
Harrington BK; Gardner HL; Izumi R; Hamdy A; Rothbaum W; Coombes KR; Covey T; Kaptein A; Gulrajani M; Van Lith B; Krejsa C; Coss CC; Russell DS; Zhang X; Urie BK; London CA; Byrd JC; Johnson AJ; Kisseberth WC
PLoS One; 2016; 11(7):e0159607. PubMed ID: 27434128
[TBL] [Abstract][Full Text] [Related]
18. CD5 Gene Signature Identifies Diffuse Large B-Cell Lymphomas Sensitive to Bruton's Tyrosine Kinase Inhibition.
Cooper A; Tumuluru S; Kissick K; Venkataraman G; Song JY; Lytle A; Duns G; Yu J; Kotlov N; Bagaev A; Hodkinson B; Srinivasan S; Smith SM; Scott DW; Steidl C; Godfrey JK; Kline J
J Clin Oncol; 2024 Feb; 42(4):467-480. PubMed ID: 38079587
[TBL] [Abstract][Full Text] [Related]
19. Distinct Roles for Bruton's Tyrosine Kinase in B Cell Immune Synapse Formation.
Roman-Garcia S; Merino-Cortes SV; Gardeta SR; de Bruijn MJW; Hendriks RW; Carrasco YR
Front Immunol; 2018; 9():2027. PubMed ID: 30237801
[TBL] [Abstract][Full Text] [Related]
20. Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma.
Nagel D; Bognar M; Eitelhuber AC; Kutzner K; Vincendeau M; Krappmann D
Oncotarget; 2015 Dec; 6(39):42232-42. PubMed ID: 26540570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
